Intravenous rhMBL in Patients With Multiple Myeloma Receiving Chemotherapy Followed by Stem Cell Transplant
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
MBL deficient patients enrolled in this protocol are scheduled to be treated with
melphalan-based high-dose chemotherapy followed by autologous hematopoietic stem cell
transplant (HSCT) for their multiple myeloma. Patients are randomized to 0.5 mg/kg, 1.0
mg/kg, or no rhMBL.